<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Functional-Remission Equivalence Theory: Biomarker-cleared PR behaves like CR for safe early discontinuation - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-28</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-28</p>
                <p><strong>Name:</strong> Functional-Remission Equivalence Theory: Biomarker-cleared PR behaves like CR for safe early discontinuation</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> Functional remission defined by PET complete metabolic response (CMR) and/or biopsy negativity—and potentially ctDNA clearance—reclassifies a subset of PR patients to CR-like relapse risk after stopping. Stopping at ~12 months is safe for PR with functional remission, whereas PR/SD without functional remission benefit from continued therapy until CMR or up to ~24 months. This reframes stopping decisions by disease activity rather than anatomic size alone.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In EA6192-like designs, PR patients with PET CMR and negative/cleared ctDNA who stop at ~12 months will achieve ≥90% 2-year EFS.</li>
                <li>Among PR/SD patients with PET non-CMR at 12 months, biopsy will reveal no viable melanoma in ≥50% of focal hypermetabolic sites; those with biopsy-negative findings who stop will have ≥85% 2-year EFS.</li>
                <li>Combining PET CMR with ctDNA negativity will improve the NPV for post-stop relapse versus either alone by ≥10% absolute.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>ctDNA clearance at 6 months combined with PET CMR at 9 months will allow even earlier safe stopping (≤12 months total) without compromising 2-year EFS, but magnitude of benefit is uncertain.</li>
                <li>Granzyme-B PET at 6–9 weeks will predict eventual PET CMR at 12 months, enabling accelerated cessation in a subset.</li>
                <li>Machine-learning integration of PET features, ctDNA kinetics, and LDH will stratify PR patients into ≥3 tiers with distinct 2-year off-therapy PFS (e.g., ≥90%, 60–80%, <50%).</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If PR+PET CMR patients who stop at ~12 months have <75% 2-year EFS in a prospective trial, the equivalence premise would be challenged.</li>
                <li>If biopsy-negative PET-avid lesions frequently harbor viable melanoma on repeat sampling or progress rapidly after stop, the biopsy-gated stop rule would be unsafe.</li>
                <li>If ctDNA negativity fails to correlate with lower relapse after stop across multiple assays and centers, ctDNA should not be used as a stop gate.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Performance of PET/ctDNA stopping gates in mucosal or acral melanoma remains unknown. <a href="../results/extraction-result-75.html#e75.0" class="evidence-link">[e75.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>